Alan Turing's iconic paper on a 'universal computing machine' goes up for auction
When you buy through links on our articles, Future and its syndication partners may earn a commission.
A trove of Alan Turing's papers, including his own personal copy of his PhD dissertation, is going up for auction June 17 after narrowly avoiding destruction.
The papers were "offprints," or copies of papers distributed in small batches within academia. They include not only Turing's signed dissertation, but also 1937's "On Computable Numbers," considered the first computer programming manual, and 1952's "The Chemical Basis of Morphogenesis," Turing's last major published work.
Turing was an English mathematician, codebreaker and one of the first computer scientists. The newly discovered papers were given by his mother, Ethel Turing, to her son's friend, fellow mathematician Norman Routledge, according to Rare Book Auctions, the company handling the sale.
After Norman's death in 2013, one of his daughters stuck the papers in her own loft. When she moved into a care home almost a decade later, one of her daughters found the papers and considered shredding them. But she asked around the family and decided to get them appraised instead, taking them along to specialists Rare Books Auctions in a carrier bag.
"Nothing could've prepared me for what I was about to find in that carrier bag," Rare Books Auction director Jim Spencer said in a statement.
The auction house is offering the papers for individual sale. They are expected to fetch a price of 40,000 to 60,000 British pounds ($54,220 to $81,324) for the copy of "On Computable Numbers," which introduced the idea of a "universal computing machine," and a similar price for the signed dissertation.
'We even have Turing's first published paper from 1935 – Equivalence of Left and Right Almost Periodicity – which is simply a single sheet of paper," Spencer said.
Ethel Turing made her gift to Routledge in May 1956, nearly two years after Turing died at age 41 on June 7, 1954. After a brilliant career at Princeton University, where he earned his doctorate, and Bletchley Park, the U.K.'s code-breaking agency, Turing worked at the U.K.'s National Physical Laboratory and the University of Manchester, where he designed some of the first forerunners of today's computers.
RELATED STORIES
—What is the Turing test, and is it still relevant?
—Alan Turing's famous mathematical model was right all along
—12 game-changing moments in the history of artificial intelligence
But in 1952, while reporting a burglary, he acknowledged a sexual relationship with another man to police and was persecuted under an 1885 law that criminalized homosexual acts as "gross indecency." To avoid prison, he was forced to submit to chemical castration — doses of estrogen that had a feminizing effect. He was also denied entry into the United States.
Turing was found dead in his home of cyanide poisoning, which may have been a result of suicide or an accident resulting from a chemistry experiment he was running at the time. His case inspired a 2009 apology from the British government and a 2017 law, known as the "Alan Turing Law," that retroactively pardons people convicted under historical legislation in England and Wales for homosexual acts.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fast Company
32 minutes ago
- Fast Company
Computer simulations reveal the first wheel was invented nearly 6,000 years ago
Imagine you're a copper miner in southeastern Europe in the year 3900 BCE. Day after day you haul copper ore through the mine's sweltering tunnels. You've resigned yourself to the grueling monotony of mining life. Then one afternoon, you witness a fellow worker doing something remarkable. With an odd-looking contraption, he casually transports the equivalent of three times his body weight on a single trip. As he returns to the mine to fetch another load, it suddenly dawns on you that your chosen profession is about to get far less taxing and much more lucrative. What you don't realize: You're witnessing something that will change the course of history—not just for your tiny mining community, but for all of humanity. Despite the wheel's immeasurable impact, no one is certain as to who invented it, or when and where it was first conceived. The hypothetical scenario described above is based on a 2015 theory that miners in the Carpathian Mountains (now Hungary) first invented the wheel nearly 6,000 years ago as a means to transport copper ore. The theory is supported by the discovery of more than 150 miniaturized wagons by archaeologists working in the region. These pint-size, four-wheeled models were made from clay, and their outer surfaces were engraved with a wickerwork pattern reminiscent of the basketry used by mining communities at the time. Carbon dating later revealed that these wagons are the earliest known depictions of wheeled transport to date. This theory also raises a question of particular interest to me, an aerospace engineer who studies the science of engineering design. How did an obscure, scientifically naive mining society discover the wheel, when highly advanced civilizations, such as the ancient Egyptians, did not? A controversial idea It has long been assumed that wheels evolved from simple wooden rollers. But until recently no one could explain how or why this transformation took place. What's more, beginning in the 1960s, some researchers started to express strong doubts about the roller-to-wheel theory. After all, for rollers to be useful, they require flat, firm terrain and a path free of inclines and sharp curves. Furthermore, once the cart passes them, used rollers need to be continually brought around to the front of the line to keep the cargo moving. For all these reasons, the ancient world used rollers sparingly. According to the skeptics, rollers were too rare and too impractical to have been the starting point for the evolution of the wheel. But a mine—with its enclosed, human-made passageways—would have provided favorable conditions for rollers. This factor, among others, compelled my team to revisit the roller hypothesis. A turning point The transition from rollers to wheels requires two key innovations. The first is a modification of the cart that carries the cargo. The cart's base must be outfitted with semicircular sockets, which hold the rollers in place. This way, as the operator pulls the cart, the rollers are pulled along with it. This innovation may have been motivated by the confined nature of the mine environment, where having to periodically carry used rollers back around to the front of the cart would have been especially onerous. The discovery of socketed rollers represented a turning point in the evolution of the wheel and paved the way for the second and most important innovation. This next step involved a change to the rollers themselves. To understand how and why this change occurred, we turned to physics and computer-aided engineering. Simulating the wheel's evolution To begin our investigation, we created a computer program designed to simulate the evolution from a roller to a wheel. Our hypothesis was that this transformation was driven by a phenomenon called ' mechanical advantage.' This same principle allows pliers to amplify a user's grip strength by providing added leverage. Similarly, if we could modify the shape of the roller to generate mechanical advantage, this would amplify the user's pushing force, making it easier to advance the cart. Our algorithm worked by modeling hundreds of potential roller shapes and evaluating how each one performed, both in terms of mechanical advantage and structural strength. The latter was used to determine whether a given roller would break under the weight of the cargo. As predicted, the algorithm ultimately converged upon the familiar wheel-and-axle shape, which it determined to be optimal. During the execution of the algorithm, each new design performed slightly better than its predecessor. We believe a similar evolutionary process played out with the miners 6,000 years ago. It is unclear what initially prompted the miners to explore alternative roller shapes. One possibility is that friction at the roller-socket interface caused the surrounding wood to wear away, leading to a slight narrowing of the roller at the point of contact. Another theory is that the miners began thinning out the rollers so that their carts could pass over small obstructions on the ground. Either way, thanks to mechanical advantage, this narrowing of the axle region made the carts easier to push. As time passed, better-performing designs were repeatedly favored over the others, and new rollers were crafted to mimic these top performers. Consequently, the rollers became more and more narrow, until all that remained was a slender bar capped on both ends by large discs. This rudimentary structure marks the birth of what we now refer to as 'the wheel.' According to our theory, there was no precise moment at which the wheel was invented. Rather, just like the evolution of species, the wheel emerged gradually from an accumulation of small improvements. This is just one of the many chapters in the wheel's long and ongoing evolution. More than 5,000 years after the contributions of the Carpathian miners, a Parisian bicycle mechanic invented radial ball bearings, which once again revolutionized wheeled transportation. Ironically, ball bearings are conceptually identical to rollers, the wheel's evolutionary precursor. Ball bearings form a ring around the axle, creating a rolling interface between the axle and the wheel hub, thereby circumventing friction. With this innovation, the evolution of the wheel came full circle. This example also shows how the wheel's evolution, much like its iconic shape, traces a circuitous path—one with no clear beginning, no end, and countless quiet revolutions along the way.


Associated Press
an hour ago
- Associated Press
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)--Jun 15, 2025-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). This press release features multimedia. View the full release here: Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF,' said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. 'As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs.' 'Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once,' said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. 'This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes.' About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs), i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells. ii,iii Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases. i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other 'force majeure' events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN N.V. Category: Precision Medicine i Raghavan, M., Wijeyesakere S.J., Peters L.R., Del Cid N. (2013) Calreticulin in the immune system: ins and outs. Trends in Immunology, 34(1):13-21. Link to source ( ) ii Nangalia J. Massie C.E., Baxter E.J., Nice F.L., et al. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine, 369(25):2391-2405. Link to source ( ) iii Klampfl T., Gisslinger, H., Harutyunyan A.S., et al. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. New England Journal of Medicine, 369(25):2379-2390. Link to source ( ) View source version on CONTACT: Contacts QIAGEN: Investor Relations [email protected] Relations [email protected] Incyte: Media [email protected] [email protected] KEYWORD: EUROPE UNITED STATES NETHERLANDS NORTH AMERICA DELAWARE INDUSTRY KEYWORD: MEDICAL DEVICES GENETICS HEALTH TECHNOLOGY BIOTECHNOLOGY HEALTH PHARMACEUTICAL OTHER SCIENCE SCIENCE ONCOLOGY SOURCE: QIAGEN N.V. Copyright Business Wire 2025. PUB: 06/15/2025 04:00 AM/DISC: 06/15/2025 03:58 AM
Yahoo
an hour ago
- Yahoo
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples Partnership supports Incyte's extensive portfolio in myeloproliferative neoplasms, including INCA033989, and enhances QIAGEN's onco-hematology diagnostics pipeline VENLO, Netherlands & WILMINGTON, Del., June 15, 2025--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. "Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs." "Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once," said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. "This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes." About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs),i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases.i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the "Risk Factors" contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN Precision Medicine i Raghavan, M., Wijeyesakere S.J., Peters L.R., Del Cid N. (2013) Calreticulin in the immune system: ins and outs. Trends in Immunology, 34(1):13-21. Link to source ( Nangalia J. Massie C.E., Baxter E.J., Nice F.L., et al. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine, 369(25):2391-2405. Link to source ( Klampfl T., Gisslinger, H., Harutyunyan A.S., et al. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. New England Journal of Medicine, 369(25):2379-2390. Link to source ( View source version on Contacts Contacts QIAGEN:Investor Relationsir@ Public Relationspr@ Contacts Incyte:Mediamedia@ Investorsir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data